Microbiome Sex-Related Diversity in Non-Muscle-Invasive Urothelial Bladder Cancer
Curr Issues Mol Biol. 2024 Apr 19;46(4):3595-3609. doi: 10.3390/cimb46040225.ABSTRACTSex-specific discrepancies in bladder cancer (BCa) are reported, and new studies imply that microbiome may partially explain the diversity. We aim to provide characterization of the bladder microbiome in both sexes diagnosed with non-muscle-invasive BCa with specific insight into cancer grade. In our study, 16S rRNA next-generation sequencing was performed on midstream urine, bladder tumor sample, and healthy-appearing bladder mucosa. Bacterial DNA was isolated using QIAamp Viral RNA Mini Kit. Metagenomic analysis was performed using hyper...
Source: Current Issues in Molecular Biology - April 26, 2024 Category: Molecular Biology Authors: Konrad Bilski Natalia Żeber-Lubecka Maria Kulecka Michalina D ąbrowska Aneta Ba łabas Jerzy Ostrowski Aleksandra Dobruch Jakub Dobruch Source Type: research
Antibody-Drug Conjugates in the Treatment of Genitourinary Cancers: An Updated Review of Data
In this study, we have thoroughly completed a narrative review of the current literature and summarized preclinical studies and clinical trials that evaluated the utility, activity, and toxicity of ADCs in GU cancers, the prospects of ADC development, and the ongoing clinical trials. Prospective clinical trials, retrospective studies, case reports, and scoping reviews were included.PMID:38668075 | PMC:PMC11049516 | DOI:10.3390/curroncol31040172 (Source: Current Oncology)
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Prathana Nathan Adnan Rajeh Meh Noor Gabriel Boldt Ricardo Fernandes Source Type: research
Active Surveillance in Non-Muscle Invasive Bladder Cancer, the Potential Role of Biomarkers: A Systematic Review
Curr Oncol. 2024 Apr 12;31(4):2201-2220. doi: 10.3390/curroncol31040163.ABSTRACTBladder cancer (BC) is the tenth most common cause of cancer worldwide and is the thirteenth leading cause of cancer mortality. The non-muscle invasive (NMI) variant represents 75% of cases and has a mortality rate of less than 1%; however, it has a high recurrence rate. The gold standard of management is transurethral resection in the case of new lesions. However, this is associated with significant morbidity and costs, so the reduction of these procedures would contribute to reducing complications, morbidity, and the burden to the health syst...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Diego Parrao Nemecio Lizana Catalina Saavedra Mat ías Larrañaga Carolina B Lindsay Ignacio F San Francisco Juan Crist óbal Bravo Source Type: research
Microbiome Sex-Related Diversity in Non-Muscle-Invasive Urothelial Bladder Cancer
Curr Issues Mol Biol. 2024 Apr 19;46(4):3595-3609. doi: 10.3390/cimb46040225.ABSTRACTSex-specific discrepancies in bladder cancer (BCa) are reported, and new studies imply that microbiome may partially explain the diversity. We aim to provide characterization of the bladder microbiome in both sexes diagnosed with non-muscle-invasive BCa with specific insight into cancer grade. In our study, 16S rRNA next-generation sequencing was performed on midstream urine, bladder tumor sample, and healthy-appearing bladder mucosa. Bacterial DNA was isolated using QIAamp Viral RNA Mini Kit. Metagenomic analysis was performed using hyper...
Source: Current Issues in Molecular Biology - April 26, 2024 Category: Molecular Biology Authors: Konrad Bilski Natalia Żeber-Lubecka Maria Kulecka Michalina D ąbrowska Aneta Ba łabas Jerzy Ostrowski Aleksandra Dobruch Jakub Dobruch Source Type: research
Antibody-Drug Conjugates in the Treatment of Genitourinary Cancers: An Updated Review of Data
In this study, we have thoroughly completed a narrative review of the current literature and summarized preclinical studies and clinical trials that evaluated the utility, activity, and toxicity of ADCs in GU cancers, the prospects of ADC development, and the ongoing clinical trials. Prospective clinical trials, retrospective studies, case reports, and scoping reviews were included.PMID:38668075 | PMC:PMC11049516 | DOI:10.3390/curroncol31040172 (Source: Current Oncology)
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Prathana Nathan Adnan Rajeh Meh Noor Gabriel Boldt Ricardo Fernandes Source Type: research
Active Surveillance in Non-Muscle Invasive Bladder Cancer, the Potential Role of Biomarkers: A Systematic Review
Curr Oncol. 2024 Apr 12;31(4):2201-2220. doi: 10.3390/curroncol31040163.ABSTRACTBladder cancer (BC) is the tenth most common cause of cancer worldwide and is the thirteenth leading cause of cancer mortality. The non-muscle invasive (NMI) variant represents 75% of cases and has a mortality rate of less than 1%; however, it has a high recurrence rate. The gold standard of management is transurethral resection in the case of new lesions. However, this is associated with significant morbidity and costs, so the reduction of these procedures would contribute to reducing complications, morbidity, and the burden to the health syst...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Diego Parrao Nemecio Lizana Catalina Saavedra Mat ías Larrañaga Carolina B Lindsay Ignacio F San Francisco Juan Crist óbal Bravo Source Type: research
Microbiome Sex-Related Diversity in Non-Muscle-Invasive Urothelial Bladder Cancer
Curr Issues Mol Biol. 2024 Apr 19;46(4):3595-3609. doi: 10.3390/cimb46040225.ABSTRACTSex-specific discrepancies in bladder cancer (BCa) are reported, and new studies imply that microbiome may partially explain the diversity. We aim to provide characterization of the bladder microbiome in both sexes diagnosed with non-muscle-invasive BCa with specific insight into cancer grade. In our study, 16S rRNA next-generation sequencing was performed on midstream urine, bladder tumor sample, and healthy-appearing bladder mucosa. Bacterial DNA was isolated using QIAamp Viral RNA Mini Kit. Metagenomic analysis was performed using hyper...
Source: Current Issues in Molecular Biology - April 26, 2024 Category: Molecular Biology Authors: Konrad Bilski Natalia Żeber-Lubecka Maria Kulecka Michalina D ąbrowska Aneta Ba łabas Jerzy Ostrowski Aleksandra Dobruch Jakub Dobruch Source Type: research
Antibody-Drug Conjugates in the Treatment of Genitourinary Cancers: An Updated Review of Data
In this study, we have thoroughly completed a narrative review of the current literature and summarized preclinical studies and clinical trials that evaluated the utility, activity, and toxicity of ADCs in GU cancers, the prospects of ADC development, and the ongoing clinical trials. Prospective clinical trials, retrospective studies, case reports, and scoping reviews were included.PMID:38668075 | PMC:PMC11049516 | DOI:10.3390/curroncol31040172 (Source: Current Oncology)
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Prathana Nathan Adnan Rajeh Meh Noor Gabriel Boldt Ricardo Fernandes Source Type: research
Active Surveillance in Non-Muscle Invasive Bladder Cancer, the Potential Role of Biomarkers: A Systematic Review
Curr Oncol. 2024 Apr 12;31(4):2201-2220. doi: 10.3390/curroncol31040163.ABSTRACTBladder cancer (BC) is the tenth most common cause of cancer worldwide and is the thirteenth leading cause of cancer mortality. The non-muscle invasive (NMI) variant represents 75% of cases and has a mortality rate of less than 1%; however, it has a high recurrence rate. The gold standard of management is transurethral resection in the case of new lesions. However, this is associated with significant morbidity and costs, so the reduction of these procedures would contribute to reducing complications, morbidity, and the burden to the health syst...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Diego Parrao Nemecio Lizana Catalina Saavedra Mat ías Larrañaga Carolina B Lindsay Ignacio F San Francisco Juan Crist óbal Bravo Source Type: research
Microbiome Sex-Related Diversity in Non-Muscle-Invasive Urothelial Bladder Cancer
Curr Issues Mol Biol. 2024 Apr 19;46(4):3595-3609. doi: 10.3390/cimb46040225.ABSTRACTSex-specific discrepancies in bladder cancer (BCa) are reported, and new studies imply that microbiome may partially explain the diversity. We aim to provide characterization of the bladder microbiome in both sexes diagnosed with non-muscle-invasive BCa with specific insight into cancer grade. In our study, 16S rRNA next-generation sequencing was performed on midstream urine, bladder tumor sample, and healthy-appearing bladder mucosa. Bacterial DNA was isolated using QIAamp Viral RNA Mini Kit. Metagenomic analysis was performed using hyper...
Source: Current Issues in Molecular Biology - April 26, 2024 Category: Molecular Biology Authors: Konrad Bilski Natalia Żeber-Lubecka Maria Kulecka Michalina D ąbrowska Aneta Ba łabas Jerzy Ostrowski Aleksandra Dobruch Jakub Dobruch Source Type: research
Antibody-Drug Conjugates in the Treatment of Genitourinary Cancers: An Updated Review of Data
In this study, we have thoroughly completed a narrative review of the current literature and summarized preclinical studies and clinical trials that evaluated the utility, activity, and toxicity of ADCs in GU cancers, the prospects of ADC development, and the ongoing clinical trials. Prospective clinical trials, retrospective studies, case reports, and scoping reviews were included.PMID:38668075 | PMC:PMC11049516 | DOI:10.3390/curroncol31040172 (Source: Current Oncology)
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Prathana Nathan Adnan Rajeh Meh Noor Gabriel Boldt Ricardo Fernandes Source Type: research
Active Surveillance in Non-Muscle Invasive Bladder Cancer, the Potential Role of Biomarkers: A Systematic Review
Curr Oncol. 2024 Apr 12;31(4):2201-2220. doi: 10.3390/curroncol31040163.ABSTRACTBladder cancer (BC) is the tenth most common cause of cancer worldwide and is the thirteenth leading cause of cancer mortality. The non-muscle invasive (NMI) variant represents 75% of cases and has a mortality rate of less than 1%; however, it has a high recurrence rate. The gold standard of management is transurethral resection in the case of new lesions. However, this is associated with significant morbidity and costs, so the reduction of these procedures would contribute to reducing complications, morbidity, and the burden to the health syst...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Diego Parrao Nemecio Lizana Catalina Saavedra Mat ías Larrañaga Carolina B Lindsay Ignacio F San Francisco Juan Crist óbal Bravo Source Type: research
Microbiome Sex-Related Diversity in Non-Muscle-Invasive Urothelial Bladder Cancer
Curr Issues Mol Biol. 2024 Apr 19;46(4):3595-3609. doi: 10.3390/cimb46040225.ABSTRACTSex-specific discrepancies in bladder cancer (BCa) are reported, and new studies imply that microbiome may partially explain the diversity. We aim to provide characterization of the bladder microbiome in both sexes diagnosed with non-muscle-invasive BCa with specific insight into cancer grade. In our study, 16S rRNA next-generation sequencing was performed on midstream urine, bladder tumor sample, and healthy-appearing bladder mucosa. Bacterial DNA was isolated using QIAamp Viral RNA Mini Kit. Metagenomic analysis was performed using hyper...
Source: Current Issues in Molecular Biology - April 26, 2024 Category: Molecular Biology Authors: Konrad Bilski Natalia Żeber-Lubecka Maria Kulecka Michalina D ąbrowska Aneta Ba łabas Jerzy Ostrowski Aleksandra Dobruch Jakub Dobruch Source Type: research
Antibody-Drug Conjugates in the Treatment of Genitourinary Cancers: An Updated Review of Data
In this study, we have thoroughly completed a narrative review of the current literature and summarized preclinical studies and clinical trials that evaluated the utility, activity, and toxicity of ADCs in GU cancers, the prospects of ADC development, and the ongoing clinical trials. Prospective clinical trials, retrospective studies, case reports, and scoping reviews were included.PMID:38668075 | PMC:PMC11049516 | DOI:10.3390/curroncol31040172 (Source: Current Oncology)
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Prathana Nathan Adnan Rajeh Meh Noor Gabriel Boldt Ricardo Fernandes Source Type: research
Active Surveillance in Non-Muscle Invasive Bladder Cancer, the Potential Role of Biomarkers: A Systematic Review
Curr Oncol. 2024 Apr 12;31(4):2201-2220. doi: 10.3390/curroncol31040163.ABSTRACTBladder cancer (BC) is the tenth most common cause of cancer worldwide and is the thirteenth leading cause of cancer mortality. The non-muscle invasive (NMI) variant represents 75% of cases and has a mortality rate of less than 1%; however, it has a high recurrence rate. The gold standard of management is transurethral resection in the case of new lesions. However, this is associated with significant morbidity and costs, so the reduction of these procedures would contribute to reducing complications, morbidity, and the burden to the health syst...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Diego Parrao Nemecio Lizana Catalina Saavedra Mat ías Larrañaga Carolina B Lindsay Ignacio F San Francisco Juan Crist óbal Bravo Source Type: research
